Furthermore, it proposes for consideration/reconsideration the assessment of IL-6 and other markers of arthritis including systemic autoantibodies and, as proposed previously, C-reactive protein [88] for monitoring the disease and therapy response in ovarian cancer. Here, CRP is linked to ovarian carcinoma.